ArticleCell biology international2025
A Proteomics Profiling Reveals the Neuroprotective Effects of Melatonin on Exogenous β-amyloid-42 Induced Mitochondrial Impairment, Intracellular β-amyloid Accumulation and Tau Hyperphosphorylation in Human SH-SY5Y Cells.
Article in Cell biology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Therapeutic Effects of miR-29b-Enriched Nanovesicles on Mitochondrial Injury and Neuroinflammatory Processes in Alzheimer's Disease.Neurotoxicity research · 2026Article
- Physiological Implications of Pancreatic Amyloid Polypeptide Aggregation and Its Inhibition by Melatonin.International journal of molecular sciences · 2026Review
- Melatonin as a Guardian of Mitochondria: Mechanisms and Therapeutic Potential in Neurodegenerative Diseases.Biology · 2026Review
- From mice to clinical relevance: humanizing neuroscience with human-based model systems.Frontiers in cellular neuroscience · 2026Review
- Physical exercise/melatonin interaction in young rats fed a low-protein diet: a behavioral, electrophysiological, and redox balance analysis.Frontiers in aging neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Alzheimer's disease (AD) is prevalent in the elderly population and characterized by the intracellular accumulation of neurofibrillary tangles (NFTs), composed of tau proteins, and extracellular deposition of beta-amyloid protein (Aβ). The present study aimed to investigate the neuroprotective effects of melatonin on Aβ42-induced AD-like pathology in SH-SY5Y cell lines. To assess the effects of melatonin on Aβ42-exposed cells, we performed a proteomics analysis of altered protein expression in Aβ42-treated cells, with or without melatonin Pretreatment, using label-free nano-LC-MS/MS. Experimental validations of pathways related to the neuroprotective effects of melatonin were carried out using Milliplex amyloid beta and tau magnetic bead assays, Western blot analysis, and measurements of mitochondrial membrane potential and ROS levels. Our results show that Aβ42 exposure led to an increase in an accumulation of intracellular Aβ42/40 and phosphorylated tau (Thr181)/Tau ratios. Pretreatment with melatonin effectively reduced the levels of these pathogenic proteins. Proteomics analysis has revealed protein markers associated with the Alzheimer's disease pathway, neuronal synapses, cellular apoptosis, and mitochondrial functions. Changes in proteins regulating the mitochondrial permeability transition pore, the electron transport chain, and mitochondrial oxidative stress were observed in Aβ42-treated cells. Pretreatment with melatonin protected the cells against Aβ42-induced cellular damages by regulating the expression of several proteins underpinning these biological processes, including the suppression of mitochondrial ROS generation and mitigation of mitochondrial membrane depolarization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.